Research Article

Enhanced oral bioavailability and gastroprotective effect of ibuprofen through mixed polymer–lipid nanoparticles

https://orcid.org/0000-0002-3746-1033

Department of Pharmacy, Faculty of Medicine & Health Sciences, Thamar University, Yemen

Search for more papers by this author

Ahmed Gardouh

*Author for correspondence: Tel.: +96 279 538 2128;

E-mail Address: Ahmed_mahmoud@pharm.suez.edu.eg

https://orcid.org/0000-0002-5387-1614

Department of Pharmaceutics & Industrial Pharmacy, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt

Department of Pharmaceutical Sciences, Faculty of Pharmacy, Jadara University, Irbid 21110, Jordan

Search for more papers by this author

Published Online:14 Apr 2021https://doi.org/10.4155/tde-2020-0125

View article

Abstract

Objectives: The aim of this study was to design and formulate mixed polymer–lipid nanoparticles (PLNs) for the delivery of ibuprofen. Methods: The mixed PLNs were prepared by a single modified emulsification solvent evaporation method. Key findings: Core-shell-shaped mixed PLNs were successfully prepared, with sizes in the nano range (193.3 ± 0.70 to 795.8 ± 0.70 nm) and ζ potential (−26.8 ± 0.45 to −42.8 ± 0.30 mV). Entrapment efficiency ranged from 80.3 to 93.6%. Conclusions: Pharmacokinetic parameters showed great improvement in C_max and T_max of ibuprofen from the formulation PLNs8 compared with the respective Brufen^® and pure drugs, indicating improvement in bioavailability of the drug.

Graphical abstract

Keywords:

Papers of special note have been highlighted as: • of interest

References

1. Li M, Luo Z, Zhao Y. Hybrid nanoparticles as drug carriers for controlled chemotherapy of cancer. Chem. Rec. 16(4), 1833–1851 (2016).
Medline CASGoogle Scholar
2. Saha RN, Vasanthakumar S, Bende G, Snehalatha M. Nanoparticulate drug delivery systems for cancer chemotherapy. Mol. Membr. Biol. 27(7), 215–231 (2010).
Medline CASGoogle Scholar
3. Dalmoro A, Bochicchio S, Nasibullin SF et al. Polymer–lipid hybrid nanoparticles as enhanced indomethacin delivery systems. Eur. J. Pharm. Sci. 121, 16–28 (2018).
Medline CASGoogle Scholar
4. Hao T, Qiao M, Li Z, Chen D. Progress in the study of pH and temperature sensitive biodegradable block copolymers. Acta Pharm. Sin. 43(2), 123–127 (2008).
CASGoogle Scholar
5. Yang X-Z, Dou S, Wang Y-C et al. Single-step assembly of cationic lipid–polymer hybrid nanoparticles for systemic delivery of siRNA. ACS Nano 6(6), 4955–4965 (2012).
Medline CASGoogle Scholar
6. Beija M, Salvayre R, Lauth-De Viguerie N, Marty J-D. Colloidal systems for drug delivery: from design to therapy. Trends Biotech. 30(9), 485–496 (2012).
Medline CASGoogle Scholar
7. Peetla C, Stine A, Labhasetwar V. Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery. Mol. Pharm. 6(5), 1264–1276 (2009).
Medline CASGoogle Scholar
8. Bose RJ, Lee S-H, Park H. Lipid polymer hybrid nanospheres encapsulating antiproliferative agents for stent applications. J. Ind. Eng. Chem. 36, 284–292 (2016).
Google Scholar
9. Hallan SS, Nidhi Kaur V, Jain V, Mishra N. Development and characterization of polymer lipid hybrid nanoparticles for oral delivery of LMWH. Artif. Cells Nanomed. Biotechnol. 45(8), 1631–1639 (2017).
Medline CASGoogle Scholar
10. Hu Y, Hoerle R, Ehrich M, Zhang C. Engineering the lipid layer of lipid–PLGA hybrid nanoparticles for enhanced in vitro cellular uptake and improved stability. Acta Biomater. 28, 149–159 (2015).
Medline CASGoogle Scholar
11. Yao C, Wu M, Zhang C et al. Photoresponsive lipid–polymer hybrid nanoparticles for controlled doxorubicin release. Nanotechnology 28(25), 255101 (2017).
MedlineGoogle Scholar
12. Jain S, Valvi PU, Swarnakar NK, Thanki K. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B. Mol. Pharm. 9(9), 2542–2553 (2012).
Medline CASGoogle Scholar
13. Kumar R, Siril PF, Javid F. Unusual anti-leukemia activity of nanoformulated naproxen and other non-steroidal anti-inflammatory drugs. Mater. Sci. Eng. C 69, 1335–1344 (2016).
Medline CASGoogle Scholar
14. Dalmoro A, Lamberti G, Titomanlio G, Barba AA, D'amore M. Enteric micro-particles for targeted oral drug delivery. AAPS Pharmscitech 11(4), 1500–1507 (2010).
Medline CASGoogle Scholar
15. Gajra B, Dalwadi C, Patel R. Formulation and optimization of itraconazole polymeric lipid hybrid nanoparticles (Lipomer) using Box Behnken design. DARU J. Pharm. Sci. 23(1), 3 (2015).
MedlineGoogle Scholar
16. Rose F, Wern JE, Ingvarsson PT et al. Engineering of a novel adjuvant based on lipid–polymer hybrid nanoparticles: a quality-by-design approach. J. Control. Release 210, 48–57 (2015).
Medline CASGoogle Scholar
17. Zhang RX, Ahmed T, Li LY, Li J, Abbasi AZ, Wu XY. Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks. Nanoscale 9(4), 1334–1355 (2017).
Medline CASGoogle Scholar
18. Mandal B, Bhattacharjee H, Mittal N et al. Core–shell-type lipid–polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine 9(4), 474–491 (2013).
Medline CASGoogle Scholar
19. Liu Y, Li K, Pan J, Liu B, Feng S-S. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of docetaxel. Biomaterials 31(2), 330–338 (2010).
Medline CASGoogle Scholar
20. Hu L, Yang J, Liu W, Li L. Preparation and evaluation of ibuprofen-loaded microemulsion for improvement of oral bioavailability. Drug Deliv. 18(1), 90–95 (2011).
Medline CASGoogle Scholar
21. Reis CP, Ferreira JP, Candeias S et al. Ibuprofen nanoparticles for oral delivery: proof of concept. J. Nanomed. Biother. Discov. 4(1), 1 (2014).
Google Scholar
22. Chan JM, Zhang L, Yuet KP et al. PLGA–lecithin–PEG core–shell nanoparticles for controlled drug delivery. Biomaterials 30(8), 1627–1634 (2009).
Medline CASGoogle Scholar
23. Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int. J. Pharm. 290(1–2), 137–144 (2005).
Medline CASGoogle Scholar
24. Kwon H-Y, Lee J-Y, Choi S-W, Jang Y, Kim J-H. Preparation of PLGA nanoparticles containing estrogen by emulsification–diffusion method. Colloids Surf. A 182(1–3), 123–130 (2001).
CASGoogle Scholar
25. Çağlar G, Yalçın S, Gündüz G, Gündüz U. Poly (DL-lactic-co-glycolic acid) microparticle-doxorubicin formulations for anti-cancer drug delivery. Eur. J. Biol. 73(1), 9–19 (2014).
Google Scholar
26. Xie S, Wang S, Zhao B, Han C, Wang M, Zhou W. Effect of PLGA as a polymeric emulsifier on preparation of hydrophilic protein-loaded solid lipid nanoparticles. Colloids Surf. B 67(2), 199–204 (2008).
Medline CASGoogle Scholar
27. Averineni RK, Shavi GV, Gurram AK et al. PLGA 50: 50 nanoparticles of paclitaxel: development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation. Bull. Mater. Sci. 35(3), 319–326 (2012).
CASGoogle Scholar
28. Yu K, Zhao J, Yu C et al. Role of four different kinds of polyethylenimines (PEIs) in preparation of polymeric lipid nanoparticles and their anticancer activity study. J. Cancer 7(7), 872 (2016).
Medline CASGoogle Scholar
29. Mancini G, Lopes RM, Clemente P et al. Lecithin and parabens play a crucial role in tripalmitin-based lipid nanoparticle stabilization throughout moist heat sterilization and freeze-drying. Eur. J. Lipid Sci. Technol. 117(12), 1947–1959 (2015).
CASGoogle Scholar
30. Varshosaz J, Ghaffari S, Khoshayand MR, Atyabi F, Azarmi S, Kobarfard F. Development and optimization of solid lipid nanoparticles of amikacin by central composite design. J. Liposome Res. 20(2), 97–104 (2010).
Medline CASGoogle Scholar
31. Vitorino C, Carvalho FA, Almeida AJ, Sousa JJ, Pais AA. The size of solid lipid nanoparticles: an interpretation from experimental design. Colloids Surf. B 84(1), 117–130 (2011).
Medline CASGoogle Scholar
32. Santander-Ortega M, Jódar-Reyes A, Csaba N, Bastos-González D, Ortega-Vinuesa J. Colloidal stability of Pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms. J. Colloid Interface Sci. 302(2), 522–529 (2006).
Medline CASGoogle Scholar
33. Sharma M, Gupta N, Gupta S. Implications of designing clarithromycin loaded solid lipid nanoparticles on their pharmacokinetics, antibacterial activity and safety. RSC Adv. 6(80), 76621–76631 (2016).
CASGoogle Scholar
34. Cho HJ, Lee DW, Marasini N et al. Optimization of self-microemulsifying drug delivery system for telmisartan using Box–Behnken design and desirability function. J. Pharm. Pharmacol. 65(10), 1440–1450 (2013).
Medline CASGoogle Scholar
35. Yalcin TE, Ilbasmis-Tamer S, Takka S. Development and characterization of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs) using central composite design. Int. J. Pharm. 548(1), 255–262 (2018).
Medline CASGoogle Scholar
36. Zhang L, Chan JM, Gu FX et al. Self-assembled lipid–polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2(8), 1696–1702 (2008).
Medline CASGoogle Scholar
37. Werner ME, Karve S, Sukumar R et al. Folate-targeted nanoparticle delivery of chemo-and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials 32(33), 8548–8554 (2011).
Medline CASGoogle Scholar
38. Wang H, Zhao P, Su W et al. PLGA/polymeric liposome for targeted drug and gene co-delivery. Biomaterials 31(33), 8741–8748 (2010).
Medline CASGoogle Scholar
39. Anderson TH, Min Y, Weirich KL, Zeng H, Fygenson D, Israelachvili JN. Formation of supported bilayers on silica substrates. Langmuir 25(12), 6997–7005 (2009).
Medline CASGoogle Scholar
40. Michel R, Gradzielski M. Experimental aspects of colloidal interactions in mixed systems of liposome and inorganic nanoparticle and their applications. Int. J. Mol. Sci. 13(9), 11610–11642 (2012).
Medline CASGoogle Scholar
41. Nurfazreen A, Julianto BT, Khuriah A. Determination of a poorly soluble drug, ibuprofen in rat plasma by a simple HPLC analysis and its application in pharmacokinetic study. Int. J. Pharm. Sci. Res. 6(1), 96102 (2015).
Google Scholar
42. Langguth P, Hanafy A, Frenzel D et al. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev. Ind. Pharm. 31(3), 319–329 (2005).
Medline CASGoogle Scholar
43. Attia MA, Enan ET, Hashish AA et al. Chemopreventive effect of 5-flurouracil polymeric hybrid PLGA–lecithin nanoparticles against colon dysplasia model in mice and impact on p53 apoptosis. Biomolecules 11(1), 109 (2021).
Medline CASGoogle Scholar
44. Bjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Lanas A. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology 154(3), 500–514 (2018).
Medline CASGoogle Scholar

Vol. 12, No. 5

Supplemental Materials

Metrics

Downloaded 246 times

History

Received 5 November 2020

Accepted 1 April 2021

Published online 14 April 2021

Published in print May 2021

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.future-science.com/doi/suppl/10.2144/tde-2020-0125

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The research protocol and animal care guidelines [201703MA2] were accepted by the institution’s research ethics committee at Faculty of Pharmacy, Suez Canal University. The NIH guidelines for use and care of laboratory animals (8th edition) were followed during the study. The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.

PDF download